Relating to the State Board of Pharmacy; and prescribing an effective date.
HB 3045 makes a set of mostly technical and administrative changes to Oregon law governing the State Board of Pharmacy. It updates the board’s authority to investigate alleged violations, issue notices and subpoenas, require certain fitness-for-practice evaluations when there are objectively reasonable grounds to question a person’s ability to practice safely, and manage the detention, embargo, condemnation, and disposal of adulterated, misbranded, or otherwise unsafe drugs and devices. The bill also revises fee-setting language for various pharmacy-related licenses and registrations and clarifies the board’s authority to receive and expend certain nonstate funds under specified conditions.
The measure also amends the criminal penalty statute for pharmacy law violations. It keeps violations of chapter 689 and board rules as misdemeanors, and it clarifies that failure to comply with board notices, citations, or subpoenas is likewise a misdemeanor, with each day of continued noncompliance treated as a separate offense. The amendments are scheduled to become operative on January 1, 2026, while the act itself takes effect 91 days after adjournment of the 2025 regular session.
HB 3045 primarily affects Oregon’s pharmacy regulatory framework by refining the State Board of Pharmacy’s enforcement powers, administrative procedures, and fee-related authority under ORS 689.135 and ORS 689.995. It does not create a new licensing scheme, but it strengthens and clarifies the board’s ability to investigate, compel evaluations, embargo unsafe products, and pursue misdemeanor enforcement for noncompliance. Pharmacists, pharmacies, drug outlets, institutional drug outlets, and nonprescription drug outlets are the main regulated parties affected.
The bill appears to have received generally favorable but not unanimous support. It passed both chambers, with comfortable margins in the House and Senate, but the recorded committee and floor votes show meaningful opposition rather than broad consensus. The absence of committee transcript discussion suggests the measure was treated largely as a technical or administrative update, though the vote totals indicate some legislators were not fully supportive.
The main points of contention likely centered on the scope of the State Board of Pharmacy’s enforcement authority, especially the power to require mental, physical, chemical dependency, or competency evaluations at the person’s expense and the misdemeanor consequences for failing to comply with board process. Some opposition may also have related to the board’s authority over embargoed or condemned drugs and devices and the breadth of its investigatory powers. Supporters likely viewed these provisions as necessary public-health and consumer-protection tools, while critics may have been concerned about regulatory burden, due process, and criminal penalties.